

November 2015



ReWalkTM
Robotics

Re Walk Robotics designs, develops,
manufactures and commercializes
wearable powered exoskeletons

*Our mission is to fundamentally change
the Quality of Life for individuals with lower
limb disability through the creation and
development of market leading robotic
technologies.*



About ReWalk Robotics (RWLK: Nasdaq)

- 1 Disruptive platform technology enabling many individuals with paralysis to walk independently
- 2 “More Than Walking”: Potential to reduce secondary medical complications & lower healthcare costs
- 3 Only exoskeleton with FDA & CE mark clearance for *both Personal & Rehabilitation use*
- 4 Demonstrated reimbursement success
- 5 Direct sales force in U.S. & Germany; distributors elsewhere in Europe & Asia
- 6 Addressing unpenetrated, multi-billion dollar market opportunity

Wheelchair confinement can cause severe physical and psychological deterioration, resulting in bad health, poor quality of life, low self-esteem and significant medical expenses.

Secondary Medical Consequences of Paralysis:

- Difficulty with bowel and urinary tract function
- Osteoporosis
- Loss of lean mass / gain in fat mass
- Insulin resistance
- Diabetes
- Heart disease



**Increased
healthcare costs due to
paraplegia-related
complications**




**Increased
need for in-home
personal device**

87% of spinal cord injury patients discharged to private, non-institutional residences

The Opportunity...


U.S. Prevalence: Spinal Cord Injury (SCI)

- 273,000 people in the U.S. living with SCI



- 12,000 new cases of SCI annually Implies \$670 mm annual market growth potential ⁽³⁾

U.S. SCI Market Potential (\$mm) ⁽²⁾



1. National Spinal Cord Injury Statistics Center (NSCISC).

2. Based on U.S. Census Bureau data.

3. Assumes 80% of 12,000 new annual injuries are candidates for ReWalk at \$70,000 per unit.

Note: The metrics provided above are forward-looking in nature and are subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company. Please refer to the Safe Harbor statement for more information.

ReWalk Personal and ReWalk Rehabilitation: designed to fundamentally change the health and life expectancies of users



Computer,
software and
batteries

Tilt sensor

Pelvic support

Motors, gears
and software

Shoe insert

- Light, wearable exoskeleton designed for all-day use
- User-initiated walking, mimicking the natural gait patterns of the legs
- Utilizes patented tilt-sensor technology
- Enables walking in multiple environments: ability to sit, stand, turn, climb and descend stairs ⁽¹⁾
- Supports its own weight; user does not expend unnecessary energy while walking
- Rechargeable battery power

Published clinical studies demonstrate ReWalk's ability to mimic a natural gait and deliver functional walking speed

1. Use of stairs is cleared under the CE mark, Canadian and Israeli registration; not cleared for stairs by the FDA in the U.S.



- Sixth generation exoskeleton, ReWalk Personal 6.0, launched Q2 2015
 - Customized fittings
 - Improved software
 - Better walking experience
 - Streamlined design
- Fastest walking speed, most natural gait and most precise fit of any exoskeleton on the market or in clinical trials
- Most customizable exoskeleton
 - Configured specifically for the user
 - Fit optimizes safety, function and joint alignment


Only Exoskeleton with FDA Clearance for Community Use



- Mimics natural walking gait
- Walking speeds as high as .71 m/s (1.6 mph/ 2.6 km/h)*


***ReWalk continues to be the
leading innovator in the industry***

Key Growth Drivers



Expanded Global Footprint

- 117 training centers globally; in 8 of the top 10 US rehab centers
- Direct field organization in the US & Germany
- Leveraging distributors to extend reach around the world
- Over 1,000 ReWalkers trained



Direct Markets

Customer Focused Organization:

- Sales
- Clinical Training
- Field Service
- Customer Support

- Direct Sales
- Distributors – Current ⁽¹⁾
- Distributors – Near-term Targets ⁽²⁾

1. Current distribution: Austria, China (including Hong Kong and Macau), France, Italy, Japan, Russia, Singapore, South Korea, Taiwan, Thailand, Turkey, UK.

2. Targeted distribution: Australia, Canada, India, Kazakhstan, Middle East, New Zealand.

Note: The metrics provided above are forward-looking in nature and are subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company. Please refer to the Safe Harbor statement for more information.

Focused on Driving Market Penetration

Direct Outreach

- Sponsorship of SCI community events
- In 8 of 10 leading rehab centers in the US

Published Data

- Largest existing body of published data for any Exoskeleton
- Further studies to quantify impact of life in a wheelchair

Market Education & Awareness

- Key professional organizations
- Media outreach
- Veterans Organizations

Building Insurance Pipeline

- 200+ leads in Q3
- 600+ Leads YTD
- 99 Insurance claims pending




Sales Cycle: 3-9 months



- Momentum in the pipeline...
 - Higher quality leads vs. year ago
 - Structured qualification process
 - More training centers at which to trial the system
- 620 Qualified leads as of Q3 '15 vs. 170 as of Q1 '15
- Reimbursement processing is the most significant contributor to the length of the sales cycle
 - Determined on a case-by-case basis
 - We are building our reimbursement capabilities
 - ✓ Enable more individuals to access ReWalk devices
 - ✓ Speed claims processing
 - ✓ Facilitate additional favorable coverage decisions
 - Efforts gaining traction in Germany

Key Initiatives Supporting Reimbursement



Significant Reimbursement Progress

Q3 '14

Self-Pay & Expanding Footprint

Q3 '15

Insurance Reimbursement

Investment in reimbursement structure and process beginning to show results

Pending Insurance Claims	Q1 '15	Q2 '15	Q3 '15
US	6	25	46
Germany	25	34	53
Total	31	59	99

- Receive FDA clearance
- No coverage approval by private US insurers
- Bronx VA announces policy to cover ReWalk
- Focus on self-pay market

- ✓ Success in US case-by-case process
- ✓ 20 of 24 favorable coverage decisions by private insurers
- ✓ 19 private payors with approved coverage decisions
- ✓ Success with workers comp & commercial payers

- ✓ 99 reimbursement claims pending
- ✓ ~50% of quarterly sales paid for by insurance
- ✓ Building German reimbursement process
- ✓ Continued collaboration with the VA on national SOP

Quantifying the Benefits of Walking

Phase I - 4 upcoming publications and studies documenting impact of SCI on the healthcare system

Commercial Payer	Single Payer (Canada)	Single Payer (Germany)	CMS
<ul style="list-style-type: none"> • Details on cost of various indication (pressure sores, UTI, etc.) • Calculate total medical costs (years 1 to 5) 	<ul style="list-style-type: none"> • Similar indications as commercial payer • Addition of Quality adjusted Life Year analysis • Bridge to Single Payer CMS 	<ul style="list-style-type: none"> • Similar indications as Canada single payer 	<ul style="list-style-type: none"> • Build from commercial payer study • Details on cost of additional indication over patients lifetime (i.e. diabetes, heart disease, depression, QoL) • Medical costs calculated over patients lifetime

Initial Study Results	Q4 2015	Q4 2015	Q1 2016	Q3 2016
Peer Reviewed Publication	Q1 2016	Q2/Q3 2016	Q3 2016	Q1 2017

Short Term

- Series of case reports to be included in white papers
- Q1 '16 - Selected cases submitted for peer review publication

Long Term

- Objective: Prospective clinical study that:
 - Documents changes in re-hospitalization, other complications, Quality of Life
 - Supports analysis of health economics
 - Initiate enrollment 1H '16
 - ◆ Follow-up at 3, 6, 12 and 24 months



VA to conduct large multi-center community-based exoskeleton study

Focus

- Quality of life
- Health benefits of walking

Scope

- 3 years
- 10 centers

ReWalk

- Only FDA cleared device for community use

Status

- VA in the process of setting up centers and securing equipment





Key Reimbursement Milestones

	2015	2016	2017
Payment Authorization	<ul style="list-style-type: none">• Hired VP of Reimbursement• Initiated payer research	<ul style="list-style-type: none">• Meet with key regional and national payer medical directors• Add staff / retain resources• Begin external appeals initiative	<ul style="list-style-type: none">• Add staff / retain resources to process appeals
Strategic Reimbursement	<ul style="list-style-type: none">• Retained Reed Smith• Commenced external appeals initiative• Kick-off partnerships with societies and KOLs	<ul style="list-style-type: none">• Potential new tech APC awarded by CMS	<ul style="list-style-type: none">• Exploratory discussions with CMS and AMA re: product and procedure coding and benefit determination
Publications	<ul style="list-style-type: none">• Developed publication strategy• Identified resources	<ul style="list-style-type: none">• Publish 1st & 2nd papers	<ul style="list-style-type: none">• Publish 3rd & 4th papers
Clinical Data	<ul style="list-style-type: none">• Complete preparation for health economics clinical study	<ul style="list-style-type: none">• Enroll patients in health economics study• 6 month followup	<ul style="list-style-type: none">• 6 month paper• 12 month followup

R&D Pipeline: Building on Our Platform

■ Existing Market ■ New Market Opportunity



ReWalk - NG

ReWalk - Q

ReWalk - MS

ReWalk - Stroke

ReWalk - Cerebral Palsy

Continued Innovation

- Next generation technology
- More efficient drive mechanism
- Slimmer profile
- Lighter body

- Quadriplegia
- Add-on sophisticated crutches

- Multiple Sclerosis
- Adaptive software to manage various disease stages

- Hemiplegia / Hemiparesis
- Adapted “half ReWalk” suit

- Enhance the Physio & Hydro therapy possibilities via motorized exoskeleton

Current R&D

Down the Road

Future

2015 YTD Highlights (thru Q3)

Financial

- Placed 31 personal and 17 rehabilitation units
- Delivered revenue of \$2.4 million

Global Footprint

- Added 13 training centers in Q3 for a total of 117 centers

Reimbursement

- Secured reimbursement coverage from 19 private payers in the US and Germany)

Demand Generation


- Generated 620 qualified leads

R&D

- Launched ReWalk Personal 6.0

Financial Snapshot

Revenues
(in millions)



Investment Highlights

- 1 Disruptive platform technology with long runway for growth
- 2 Leading technology with unmatched regulatory clearance - only exoskeleton with FDA & CE mark clearance
- 3 Demonstrated reimbursement success in the U.S. and abroad
- 4 Growing worldwide presence with expanding sales and distribution platform in the U.S., Europe and Asia building strong demand pipeline
- 5 Growing body of clinical data supporting secondary health benefits of walking
- 6 Platform technology with broad opportunities for long-term growth through additional indications

Investor Contact

Lisa Wilson

In-Site Communications, Inc.

T: (212) 452-2793

E: lwilson@insitecony.com